Cite
HARVARD Citation
Lewis, K. et al. (2019). Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib. European journal of cancer. pp. 45-55. [Online].